Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system

BMC Clinical Pharmacology

Staffan Hägg¹  Mikael Holmlund¹  Henrik Lövborg² 

[1] Department of Clinical Pharmacology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden;Clinical Pharmacology, University Hospital, S-581 85 Linköping, Sweden

关键词: Incident reporting system;    Medication errors;    Buprenorphine;    Fentanyl;    Opioids;    Transdermal patch;   

Others  :  860317
DOI  :  10.1186/2050-6511-15-31

 received in 2013-11-15, accepted in 2014-05-20,  发布年份 2014

【 摘 要 】

Objective

A few cases of adverse reactions linked to erroneous use of transdermal opioid patches have been reported in the literature. The aim of this study was to describe and characterize medication errors (MEs) associated with use of transdermal fentanyl and buprenorphine.

Methods

All events concerning transdermal opioid patches reported between 2004 and 2011 to a regional incident reporting system and assessed as MEs were scrutinized and characterized. MEs were defined as “a failure in the treatment process that leads to, or has the potential to lead to, harm to the patient”.

Results

In the study 151 MEs were identified. The three most common error types were wrong administration time 67 (44%), wrong dose 34 (23%), and omission of dose 20 (13%). Of all MEs, 118 (78%) occurred in the administration stage of the medication process. Harm was reported in 26 (17%) of the included cases, of which 2 (1%) were regarded as serious harm (nausea/vomiting and respiratory depression). Pain was the most common adverse reaction reported.

Conclusions

Of the reported MEs related to transdermal fentanyl and buprenorphine, most occurred during administration. Improved routines to ascertain correct and timely administration and educational interventions to reduce MEs for these drugs are warranted.

【 授权许可】

   
2014 Lövborg et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Durand C, Alhammad A, Willett KC: Practical considerations for optimal transdermal drug delivery. Am J Health Syst Pharm 2012, 69:116-124.
• [2]Wohlrab J, Kreft B, Tamke B: Skin tolerability of transdermal patches. Expert Opin Drug Deliv 2011, 8:939-948.
• [3]Fentanyl patches: preventable overdose Prescrire Int 2010, 19:22-25.
• [4]Lövborg H, Jönsson AK, Hägg S: A fatal outcome after unintentional overdosing of rivastigmine patches. Curr Drug Saf 2012, 7:30-32.
• [5]Mrvos R, Feuchter AC, Katz KD, Duback-Morris LF, Brooks DE, Krenzelok EP: Whole fentanyl patch ingestion: a multi-center case series. J Emerg Med 2012, 42:549-552.
• [6]Sindali K, Sherry K, Sen S, Dheansa B: Life-threatening coma and full-thickness sunburn in a patient treated with transdermal fentanyl patches: a case report. J Med Case Reports 2012, 6:220. BioMed Central Full Text
• [7]Lee M, Phillips J: Transdermal patches: high risk for error? Drug Topics 2002, 54-55.
• [8]Fentanyl Transdermal System (marketed as Duragesic) Information [ http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm114961.htm webcite]
• [9]Grissinger M, Gaunt MJ: Reducing patient harm with the use of fentanyl transdermal system. Consult Pharm 2009, 24:864-872.
• [10]Hoffman RS, Manini AF, Russell-Haders AL, Felberbaum M, Mercurio-Zappala M: Use of pralidoxime without atropine in rivastigmine (carbamate) toxicity. Hum Exp Toxicol 2009, 28:599-602.
• [11]The act concerning the ethical review of research involving humans Swedish Code of Statutes 2003., 460
• [12]Ferner RE, Aronson JK: Clarification of terminology in medication errors: definitions and classification. Drug Saf 2006, 29:1011-1022.
• [13]World Health Organisation Collaborating Centre for International Drug Monitoring: adverse reaction terminology [ http://www.who-umc.org webcite]
• [14]MedDRA - Medical Dictionary for Regulatory Activities [ http://www.meddra.org/ webcite]
• [15]Lisby M, Nielsen LP, Brock B, Mainz J: How should medication errors be defined? Development and test of a definition. Scand J Public Health 2012, 40:203-210.
• [16]Reason J: Human error: models and management. BMJ 2000, 320:768-770.
• [17]Kornick CA, Santiago-Palma J, Moryl N, Payne R, Obbens EAMT: Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003, 26:951-973.
• [18]Kress HG, Boss H, Delvin T, Lahu G, Lophaven S, Marx M, Skorjanec S, Wagner T: Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent. Eur J Pharm Biopharm 2010, 75:225-231.
• [19]Jozefczyk KG, Kennedy WK, Lin MJ, Achatz J, Glass MD, Eidam WS, Melroy MJ: Computerized prescriber order entry and opportunities for medication errors: comparison to tradition paper-based order entry. J Pharm Pract 2013, 26:434-437.
• [20]Villamanan E, Larrubia Y, Ruano M, Velez M, Armada E, Herrero A, Alvarez-Sala R: Potential medication errors associated with computer prescriber order entry. Int J Clin Pharm 2013, 35:577-583.
• [21]Kim HK, Smiddy M, Hoffman RS, Nelson LS: Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics 2012, 130:e1700-e1703.
• [22]Clemens KE, Klaschik E: Clinical experience with transdermal and orally administered opioids in palliative care patients–a retrospective study. Jpn J Clin Oncol 2007, 37:302-309.
• [23]Dy SM, Shore AD, Hicks RW, Morlock LL: Medication errors with opioids: results from a national reporting system. J Opioid Manage 2007, 3:189-194.
• [24]Tanner T, Marks R: Delivering drugs by the transdermal route: review and comment. Skin Res Tech 2008, 14:249-260.
• [25]Pintor-Mármol A, Baena M: Terms used in patient safety related to medication: a literature review. Pharmacoepidemiol Drug Saf 2012, 21:799-809.